These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39085330)

  • 1. Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off.
    Leodori G; Mancuso M; Maccarrone D; Tartaglia M; Ianniello A; Certo F; Ferrazzano G; Malimpensa L; Belvisi D; Pozzilli C; Berardelli A; Conte A
    Sci Rep; 2024 Jul; 14(1):17654. PubMed ID: 39085330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural bases of motor fatigue in multiple sclerosis: A multimodal approach using neuromuscular assessment and TMS-EEG.
    Leodori G; Mancuso M; Maccarrone D; Tartaglia M; Ianniello A; Certo F; Baione V; Ferrazzano G; Malimpensa L; Belvisi D; Pozzilli C; Berardelli A; Conte A
    Neurobiol Dis; 2023 May; 180():106073. PubMed ID: 36906073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study.
    Liepert J; Mingers D; Heesen C; Bäumer T; Weiller C
    Mult Scler; 2005 Jun; 11(3):316-21. PubMed ID: 15957514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.
    van Kempen ZLE; Doesburg D; Dekker I; Lissenberg-Witte BI; de Vries A; Claessen IA; Brinke AT; Rispens T; Killestein J
    Neurology; 2019 Oct; 93(17):e1579-e1586. PubMed ID: 31551258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    Toorop AA; Wessels MHJ; Gelissen LMY; Hoitsma E; Zeinstra EMPE; van Rooij LC; van Munster CEP; Vennegoor A; Mostert JP; Wokke BHA; Kalkers NF; Hoogervorst ELJ; van Eijk JJJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige LGF; Kloosterziel ME; Arnoldus EPJ; van Dijk GW; Bouvy WH; Strijbis EMM; van Oosten BW; de Jong BA; Lissenberg-Witte BI; Rispens T; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    J Neurol Sci; 2024 Jul; 462():123102. PubMed ID: 38925067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic.
    Bringeland GH; Blaser N; Myhr KM; Vedeler CA; Gavasso S
    J Neurol Sci; 2021 Oct; 429():117622. PubMed ID: 34474301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis.
    Meuth SG; Bittner S; Seiler C; Göbel K; Wiendl H
    Mult Scler; 2011 Feb; 17(2):198-203. PubMed ID: 21135021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
    Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L
    Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
    Wickström A; Dahle C; Vrethem M; Svenningsson A
    Mult Scler; 2014 Jul; 20(8):1095-101. PubMed ID: 24378984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
    Bringeland GH; Blaser N; Myhr KM; Vedeler CA; Gavasso S
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes C; Fernandes C; Cunha C; Nunes C; Macário C; Sousa L; Batista S; Correia I
    J Neurol Sci; 2024 Mar; 458():122930. PubMed ID: 38368641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. People with multiple sclerosis have reduced TMS-evoked motor cortical output compared with healthy individuals during fatiguing submaximal contractions.
    Brotherton EJ; Sabapathy S; Mckeown DJ; Kavanagh JJ
    J Neurophysiol; 2022 Jul; 128(1):105-117. PubMed ID: 35675447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-exercise facilitation and depression of motor evoked potentials to transcranial magnetic stimulation: a study in multiple sclerosis.
    Perretti A; Balbi P; Orefice G; Trojano L; Marcantonio L; Brescia-Morra V; Ascione S; Manganelli F; Conte G; Santoro L
    Clin Neurophysiol; 2004 Sep; 115(9):2128-33. PubMed ID: 15294215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study.
    Bringeland GH; Myhr KM; Vedeler CA; Gavasso S
    J Neurol Sci; 2020 Aug; 415():116880. PubMed ID: 32413799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
    Mainero C; Inghilleri M; Pantano P; Conte A; Lenzi D; Frasca V; Bozzao L; Pozzilli C
    Neurology; 2004 Jun; 62(11):2044-50. PubMed ID: 15184612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice-dependent motor cortex plasticity is reduced in non-disabled multiple sclerosis patients.
    Stampanoni Bassi M; Buttari F; Maffei P; De Paolis N; Sancesario A; Gilio L; Pavone L; Pasqua G; Simonelli I; Sica F; Fantozzi R; Bellantonio P; Centonze D; Iezzi E
    Clin Neurophysiol; 2020 Feb; 131(2):566-573. PubMed ID: 31818686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.